Astute Medical, Inc. – Trademark Portfolio
Entity Type: 03
Astute Medical, Inc. holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 4 Nice Classification classes. Currently, 8 trademarks are registered. Notable registered marks include N, ASTUTE, ASTUTE140, ASTUTE 140, and NEPHROCHECK. The owner is based in San Diego, CA.
Bldg 2, R. 645
3550 General Atomics Court
San Diego, CA 92121
Showing of trademarks Trademarks
Trademark Classifications
Astute Medical, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Astute Medical, Inc. have?
Astute Medical, Inc. has 18 U.S. trademarks filed with the USPTO. Of these, 8 registered, 7 abandoned, 3 cancelled.
What trademark classes does Astute Medical, Inc. file in?
Astute Medical, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 9 (Computers & Electronics), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Astute Medical, Inc.'s most well-known trademarks?
Astute Medical, Inc.'s registered trademark portfolio includes well-known marks such as N, ASTUTE, ASTUTE140, ASTUTE 140, and NEPHROCHECK. These are among 8 currently registered trademarks in the portfolio.
What is Astute Medical, Inc.'s trademark registration success rate?
Astute Medical, Inc. has a 44% trademark registration rate, with 8 out of 18 resolved applications resulting in successful registration. Currently, 0 applications are pending review.